- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00826319
Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time (CanPREDDICT)
27. november 2013 opdateret af: University of British Columbia
CanPREDDICT: Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time
This study will follow 2500 prevalent Chronic Kidney Disease (CKD) patients with Glomerular Filtration Rate (GFR) from 15-45 ml/min for 30 months with serial measurements every 6 months and subsequent annual chart review up to 60 months.
This observational study will analyze the demographics, clinical status, medications and blood and urine samples of these patients and study the conventional biochemical, hormonal and metabolic parameters assessing which underlying biomarkers reflect the processes involved with disease progression.
Studieoversigt
Status
Ukendt
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
2602
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada
- Foothills Hospital
-
Edmonton, Alberta, Canada
- University of Alberta
-
-
British Columbia
-
Penticton, British Columbia, Canada
- Penticton Regional Hospital
-
Vancouver, British Columbia, Canada
- Vancouver General Hospital
-
Vancouver, British Columbia, Canada
- BC Children's Hospital
-
Vancouver, British Columbia, Canada
- St. Paul's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- St. Boniface Hospital
-
-
Newfoundland and Labrador
-
St John's, Newfoundland and Labrador, Canada
- Eastern Regional Health Authority, Health Sciences Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- QEII Health Sciences Centre
-
Sydney, Nova Scotia, Canada
- Cape Breton District Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canada
- St Joseph's Hospital
-
Kingston, Ontario, Canada
- Kingston General Hospital
-
London, Ontario, Canada
- London Health Science Centre- Victoria Campus
-
London, Ontario, Canada
- London Health Science Centre- University Campus
-
Oak Ridges, Ontario, Canada
- York Central
-
Ottawa, Ontario, Canada
- University of Ottawa
-
Timmins, Ontario, Canada
- Timmins & District Hospital
-
Toronto, Ontario, Canada
- St. Michael's Hospital
-
Toronto, Ontario, Canada
- University Health Network
-
Toronto, Ontario, Canada
- Sunnybrook Hospital
-
-
Quebec
-
Greenfield Park, Quebec, Canada
- Charles Le Moyne Hospital
-
Montreal, Quebec, Canada
- Royal Victoria Hospital
-
Montreal, Quebec, Canada
- Hopital du Sacre-Coeur
-
Montréal, Quebec, Canada
- Maisonneuve-Rosemont Hopital
-
Quebec City, Quebec, Canada
- CHUQ: L'Hôtel-Dieu de Québec
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
19 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Nephrology Clinics across Canada
Beskrivelse
Inclusion Criteria:
- Patients currently seen by a nephrologist, or referred for evaluation of CKD
- GFR between 15-45 ml/min
- Adults 19 years (depending on age of consent in province) or older
- At pediatric sites study participants will be eligible to participate at age 15 or older
Exclusion Criteria:
- Organ transplant recipient
- Life expectancy less than 12 months
- Acute Vasculitis
- Bioimpedance sub-study exclusion criteria:
- Amputation (readings are inaccurate)
- Any battery operated or electronic implanted device (such as pacemaker or implanted defibrillator - potential electrical hazard)
- Pregnant women
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Bioimpedance sub-study cohort
Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population.
The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events.
Subjects are followed at 6 months intervals for 2 years.
|
Ethnic enrichment cohort
Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
|
Original CanPreddict cohort
The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Renal Replacement Therapy
Tidsramme: 6 monthly for 3 years, annually up to 5 years
|
Renal Replacement Therapy is defined as dialysis start or transplantation.
|
6 monthly for 3 years, annually up to 5 years
|
Cardiovascular events
Tidsramme: 6 monthly for 3 years, annually up to 5 years
|
Cardiovascular events are defined as myocardial infarction, ischemic and hemorrhagic stroke, coronary revascularization, congestive heart failure, peripheral bypass and gangrenes, adjudicated by a nephrologist, cardiologist and neurologist.
|
6 monthly for 3 years, annually up to 5 years
|
Death
Tidsramme: 6 monthly for 3 years, annually up to 5 years
|
Deaths are reported with source documentation and adjudicated for ischemic or congestive cardiovascular death, other cardiovascular death, non-cardiovascular death and unknown cause of death.
|
6 monthly for 3 years, annually up to 5 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Adeera Levin, University of British Columbia
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Levin A, Rigatto C, Brendan B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O; CanPREDDICT investigators. Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol. 2013 Jun 11;14:121. doi: 10.1186/1471-2369-14-121.
- Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase C, Tang M, Djurdjev O. (2012). Canadian study of prediciont of death, dialysis and interim cardiovascular events: CanPREDDICT: Biomarkers improve prediction of one year outcomes in chronic kidney disease cohort. Clinical studies in CKD. Nephrology Dialysis Transplantation, 27(suppl 2), ii63-ii65.
- Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O; CanPREDDICT Investigators. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant. 2014 May;29(5):1037-47. doi: 10.1093/ndt/gft479. Epub 2013 Dec 26.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juni 2008
Primær færdiggørelse (Forventet)
1. december 2014
Studieafslutning (Forventet)
1. december 2014
Datoer for studieregistrering
Først indsendt
20. januar 2009
Først indsendt, der opfyldte QC-kriterier
21. januar 2009
Først opslået (Skøn)
22. januar 2009
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
28. november 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
27. november 2013
Sidst verificeret
1. november 2013
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- H07-02457
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kronisk nyresygdom
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Novartis PharmaceuticalsLedigPrimær myelofibrose (PMF) | Polycytæmi Vera (PV) | Post polycytæmi myelofibrose (PPV MF) | Trombocytæmi myelofibrose (PET-MF) | Alvorlig/meget svær COVID-19 sygdom | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)